Viewing Study NCT01826266

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 4:12 PM
Ignite Modification Date: 2026-01-24 @ 4:09 AM
Study NCT ID: NCT01826266
Status: COMPLETED
Last Update Posted: 2020-05-28
First Post: 2013-04-03
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban
Sponsor: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Anticoagulant Reversal View
None Reversal of Edoxaban Induced Anticoagulation View
Keywords:

Keywords

Keyword Brief Keyword Text View
None PER977 View
None Activated partial thromboplastin time View
None Assessment View
None D-dimer View
None Enrollment View
None Investigational drug View
None Investigational treatment View
None Period View
None Premature subject withdrawal View
None Prothrombin time View
None Randomization number View
None Study discontinuation View
None Study drug View
None Subject number View
None Study treatment View
None Thromboelastography-reaction time View